XML 34 R35.htm IDEA: XBRL DOCUMENT v3.3.0.814
Fair Value Measurements (Acquisition of CyDex) (Details) - Cydex Pharmaceuticals, Inc - USD ($)
$ in Millions
9 Months Ended 12 Months Ended
Sep. 30, 2015
Dec. 31, 2014
Credit Derivatives [Line Items]    
Amount Of Revenue For Contingent Consideration $ 15.0  
Contingent Consideration Classified as Equity    
Credit Derivatives [Line Items]    
Revenue volatility 25.00% 25.00%
Average of probability of commercialization 88.00% 81.00%
Sales beta 0.50 0.60
Credit rating B B
Equity risk premium 6.00% 6.00%
Minimum | Contingent Consideration Classified as Equity    
Credit Derivatives [Line Items]    
Range of annual revenue subject to revenue sharing $ 20.7 $ 17.2
Maximum | Contingent Consideration Classified as Equity    
Credit Derivatives [Line Items]    
Range of annual revenue subject to revenue sharing $ 24.6 $ 17.3